alexander perl, eha 2019 – the phase iii admiral trial
Published 5 years ago • 158 plays • Length 7:36
Download video MP4
Download video MP3
Similar videos
-
6:22
eha 2019 alexander perl
-
2:53
paolo ghia, eha 2019 – ascend phase iii study
-
5:53
jo howard, eha 2019 – results from the hope trial
-
5:10
andrea gallamini, eha 2019 – three-year update of the echelon-1 study
-
0:32
alexander perl, md on treatment based on the phase iii study evaluating cpx-351 (vyxeos) versus 7 3
-
1:07:54
management of flt3 positive aml with dr. alexander perl
-
1:01
alexander perl, md, on how the beat aml master trial will change the way aml patients are treated
-
1:20:22
15th willem c. vis east moot court, 2018 - finals (albert ludwigs v/s. ils)
-
5:36
epcoritamab's impact on treating relapsed follicular lymphoma | umberto vitolo, md | eha 2024
-
7:07
asco/eha 2024 myeloma highlights | ajai chari, md | eha 2024
-
4:04
dr. alexander perl, m.d., associate professor of medicine at the university of pennsylvania
-
0:41
alexander perl, md, on the toxicity in the phase 3 study evaluating cpx-351 (vyxeos)
-
5:14
prithviraj bose md, eha 2019 – sotatercept in subjects with mpn-associated myelofibrosis and anaemia
-
5:28
ibrahim el houssieny, eha 2019 – car-t cells and manufacturing (part 1)
-
1:25
alexander perl, md, on importance of flt3 and provides his perspective on inhibitor differences
-
1:22
alexander perl, md, on aml trial results presented at this year’s ash meeting
-
3:06
antonis kattamis, eha 2019 – transfusion-dependent thalassemia and the deep-2 trial
-
0:20
eha 2019 – day 1 highlights!
-
1:57
day three of mpe´s coverage at eha 2024
-
1:23
alexander perl, md discusses cpx-351 (vyxeos) mechanism of action and why it is a promising agent
Clip.africa.com - Privacy-policy